Alendronate and Denosumab Use in Hemodialysis Patients

Introduction to Treatment Options

The American College of Cardiology is not mentioned, however, Kidney International recommends that denosumab is the preferred agent over alendronate for osteoporosis treatment in hemodialysis patients due to superior safety data in this population 1

Bisphosphonates, including alendronate, are generally contraindicated in advanced kidney disease due to nephrotoxicity concerns, as stated by the Journal of Clinical Oncology 1, 2
For patients with severe renal impairment, standard guidelines recommend avoiding or using extreme caution with bisphosphonates, according to the Journal of Clinical Oncology 3

Oral alendronate requires careful administration to avoid esophageal irritation, which may be problematic in dialysis patients, as noted by the American Journal of Kidney Diseases 4, 5, 6

Current guidelines favor denosumab over alendronate for hemodialysis patients with osteoporosis, though limited data exist comparing their safety profiles directly, according to Kidney International 1
Denosumab does not require renal dose adjustment and has lower renal toxicity compared to bisphosphonates, as stated by Kidney International 1
The primary concern with denosumab in dialysis patients is severe hypocalcemia, which requires aggressive prophylaxis and monitoring, according to Kidney International 1
Additional risks include osteonecrosis of the jaw, atypical femoral fractures, and rebound bone resorption upon discontinuation, as noted by Kidney International 7

Monitor serum calcium, phosphorus, magnesium, and intact PTH levels regularly, and evaluate for albuminuria every 3-6 months; discontinue if unexplained albuminuria ≥500 mg/24 hours develops, as recommended by the Journal of Clinical Oncology 3
Never use short infusion times with bisphosphonates in dialysis patients, according to the Journal of Clinical Oncology 3

For patients with osteoporosis/osteopenia and impaired renal function, denosumab is the preferred treatment option due to its safety profile in renal impairment, while bisphosphonates should be used with caution or avoided depending on the severity of renal dysfunction 8, 9
If GFR is between 30-60 mL/min, reduced dosage of zoledronic acid with no changes in infusion time or interval, and pamidronate administered over 4-6 hours for patients with extensive bone disease, with monitoring of serum creatinine before each dose of bisphosphonate therapy 10, 11
For patients with severe renal impairment (GFR <30 mL/min), denosumab can be considered with careful monitoring of calcium levels and concomitant vitamin D supplementation 9
Regular monitoring of renal function before each dose of bisphosphonate, and intermittent evaluation (every 3-6 months) for albuminuria in patients receiving IV bisphosphonates 10, 11
For patients on denosumab, monitor calcium levels closely to prevent hypocalcemia 8, 9

Systemic corticosteroids used during COPD exacerbations can worsen bone loss, especially in patients already at risk for osteoporosis, and consideration should be given to shorter courses of steroids and monitoring for steroid-induced hyperglycemia 12
Ensure adequate calcium intake through diet or supplements while monitoring calcium levels in patients with COPD and osteoporosis 8, 9

Do not use calcium-containing phosphate binders in dialysis patients with hypercalcemia 13
Be cautious with denosumab in patients with severe renal impairment due to risk of hypocalcemia; ensure adequate vitamin D levels before initiating therapy 9
Avoid short infusion times with pamidronate or zoledronic acid in patients with renal impairment 10, 11